Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Journal of Neurosurgical Sciences 2017 October;61(5) > Journal of Neurosurgical Sciences 2017 October;61(5):495-503



To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Journal of Neurosurgical Sciences 2017 October;61(5):495-503

DOI: 10.23736/S0390-5616.16.03263-X


language: English

Neuroprotective effects of pregabalin in a rat model of intracisternal facial nerve avulsion

Shigeta MORIYA 1, Mitsuhiro HASEGAWA 1, Joji INAMASU 1 , Hirotaka KOGAME 1, Yuichi HIROSE 1, Ryo HIGASHI 2, Makoto ITO 3, Fumihiro IMAI 4

1 Department of Neurosurgery, Fujita Health University School of Medicine, Toyoake, Japan; 2 Department of Neurosurgery, Komatsu Municipal Hospital, Komatsu, Japan; 3 Department of Pediatric Otolaryngology, Jichi Children’s Medical Center Tochigi, Jichi Medical University, Shimotsuke, Japan; 4 Ichiriyama-Imai Clinic, Kariya, Japan


BACKGROUND: Pregabalin (PGB), a drug used for treating neuropathic pain, has immune-modulating property that may have therapeutic implications. Suppression of microglial activation and improvement in functional recovery was observed in experimental spinal cord injury after PGB administration. An experimental study was conducted to evaluate whether PGB could afford neuroprotection in a rat model of intracisternal facial nerve avulsion.
METHODS: Twenty-eight male Wistar rats (250-300 g) were dichotomized into two groups: a PGB group (N.=14) and a control group (N.=14). The PGB group received a total of 4 intraperitoneal PGB injections (30 mg/kg, 15 minutes preoperatively and 4, 24, and 48 hours postoperatively), and the control group underwent intraperitoneal saline injection. Intracisternal facial nerve avulsion was created by tangential pull-out of the nerve surgically exposed at the stylomastoid foramen. In both groups, the brainstem containing the facial motor nuclei neurons was thin-sliced and stained with cresyl violet, and the number of viable neurons in the facial motor nuclei on days 14 and 28 was counted under microscope.
RESULTS: The total viable neuron count was significantly greater in the PGB group than in the Control group both on day 14 (271.4±14.9 vs. 196.2±22.2, P<0.01) and day 28 (160.2±21.6 vs. 102.6±13.4, P<0.01). Furthermore, CD11b/c immunostaining on days 3 and 8 showed that CD11b/c-positive cells, suggestive of activated microglia, were observed only in the control group.
CONCLUSIONS: Better neuronal survival by PGB administration may be beneficial and clinically relevant when surgical reconstruction of the facial nerve, such as hypoglossal-facial nerve anastomosis, is considered.

KEY WORDS: Facial nerve injuries - Microglia - Neuroprotection - Pregabalin

top of page